|
rs121434592
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Both assays are employed at centralized testing laboratories operating according to quality standards for prospective identification of the AKT1 E17K mutation in ER+ breast cancer patients in the context of a clinical trial evaluating the AKT inhibitor AZD5363 in combination with endocrine (fulvestrant) therapy.
|
28472036 |
2017 |
|
rs13267382
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The remaining two gene-environment interactions were also identified in relation to ER- breast cancer risk and were found between 3p21-rs6796502 and age at menarche (OR<sub>int</sub> = 1.26, 95% CI: 1.12-1.43, p<sub>int</sub> =1.8 × 10<sup>-4</sup> ) and between 8q23-rs13267382 and age at first full-term pregnancy (OR<sub>int</sub> = 0.89, 95% CI: 0.83-0.95, p<sub>int</sub> = 5.2 × 10<sup>-4</sup> ).
|
28670784 |
2017 |
|
rs190843378
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PRKAG3 (Padj = 0.0018) and RPS6KA3 (Padj = 0.061) were the leading genes for the associations with overall breast cancer risk and ER- breast cancer risk, respectively. rs190843378 in PRKAG3 was statistically significant after gene-level adjustment for multiple comparisons (OR = 0.50 for each T allele, 95% CI = 0.38-0.66, Padj = 3.6E-05), with a statistical power of 0.914.
|
28582508 |
2017 |
|
rs200847762
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In stratification analyses, we found that the protective effect of rs200847762 was stronger in ER-positive breast cancer (OR = 0.18, 95% CI = 0.06-0.42) than that in ER-negative one (OR = 0.59, 95% CI = 0.31-1.05).
|
27479355 |
2017 |
|
rs6796502
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The remaining two gene-environment interactions were also identified in relation to ER- breast cancer risk and were found between 3p21-rs6796502 and age at menarche (OR<sub>int</sub> = 1.26, 95% CI: 1.12-1.43, p<sub>int</sub> =1.8 × 10<sup>-4</sup> ) and between 8q23-rs13267382 and age at first full-term pregnancy (OR<sub>int</sub> = 0.89, 95% CI: 0.83-0.95, p<sub>int</sub> = 5.2 × 10<sup>-4</sup> ).
|
28670784 |
2017 |
|
rs10069690
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry.
|
28171663 |
2016 |
|
rs10822013
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs142697907
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gene-based analyses revealed that CDH1 was responsible for the pathway association (P < 0.01), with rs4783673 in CDH1 statistically significant after gene-level adjustment for multiple comparisons (P = 9.2×10(-5), corrected P = 0.02). rs142697907 in PTPN14 was associated with ER-positive breast cancer and rs2456773 in CDK1 with ER-negativity in case-only analysis after gene-level correction for multiple comparisons (corrected P < 0.05).
|
27485598 |
2016 |
|
rs1432679
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs2456773
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gene-based analyses revealed that CDH1 was responsible for the pathway association (P < 0.01), with rs4783673 in CDH1 statistically significant after gene-level adjustment for multiple comparisons (P = 9.2×10(-5), corrected P = 0.02). rs142697907 in PTPN14 was associated with ER-positive breast cancer and rs2456773 in CDK1 with ER-negativity in case-only analysis after gene-level correction for multiple comparisons (corrected P < 0.05).
|
27485598 |
2016 |
|
rs4783673
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gene-based analyses revealed that CDH1 was responsible for the pathway association (P < 0.01), with rs4783673 in CDH1 statistically significant after gene-level adjustment for multiple comparisons (P = 9.2×10(-5), corrected P = 0.02). rs142697907 in PTPN14 was associated with ER-positive breast cancer and rs2456773 in CDK1 with ER-negativity in case-only analysis after gene-level correction for multiple comparisons (corrected P < 0.05).
|
27485598 |
2016 |
|
rs4973768
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs704010
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs981782
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs370815401
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This descriptive study examines correlations between concentrations of tamoxifen's glucuronide metabolites and genotypes UGT1A4 Pro24Thr, UGT1A4 Leu48Val, UGT2B7 His268Tyr, UGT2B15 Asp85YTyr UGT2B15 Lys523Thr and UGT2B17del in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen.
|
26176234 |
2015 |
|
rs4148269
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This descriptive study examines correlations between concentrations of tamoxifen's glucuronide metabolites and genotypes UGT1A4 Pro24Thr, UGT1A4 Leu48Val, UGT2B7 His268Tyr, UGT2B15 Asp85YTyr UGT2B15 Lys523Thr and UGT2B17del in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen.
|
26176234 |
2015 |
|
rs2016347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We provide the first evidence for IGF1R_rs2016347 as an independent prognostic marker for ER+ breast cancer patients treated with TAM and support a rational for combined treatment strategies.
|
23459444 |
2014 |
|
rs4849887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Statistically significant differences were detected with the association of rs6828523 (4q34.1/ADAM29) with ER-positive breast cancer (P = 1.27 × 10(-3)) and the association of rs4849887 (2q14.2) with PR-positive breast cancer (P = 1.29 × 10(-3)).
|
25007960 |
2014 |
|
rs6828523
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Statistically significant differences were detected with the association of rs6828523 (4q34.1/ADAM29) with ER-positive breast cancer (P = 1.27 × 10(-3)) and the association of rs4849887 (2q14.2) with PR-positive breast cancer (P = 1.29 × 10(-3)).
|
25007960 |
2014 |
|
rs2051579
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings show a suggestively stronger association between FGFR2 rs2981582 and ER-positive breast cancer risk and suggest a greater association of FGF1 rs250108 and RBFOX2 rs2051579 with ER-negative compared to ER-positive breast cancer.
|
23143756 |
2013 |
|
rs250108
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings show a suggestively stronger association between FGFR2 rs2981582 and ER-positive breast cancer risk and suggest a greater association of FGF1 rs250108 and RBFOX2 rs2051579 with ER-negative compared to ER-positive breast cancer.
|
23143756 |
2013 |
|
rs2981582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings show a suggestively stronger association between FGFR2 rs2981582 and ER-positive breast cancer risk and suggest a greater association of FGF1 rs250108 and RBFOX2 rs2051579 with ER-negative compared to ER-positive breast cancer.
|
23143756 |
2013 |
|
rs6788895
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although none of the SNPs showed an overall association with breast cancer, an analysis of the ER status of the breast cancer patients revealed that the SIAH2 locus (rs6788895; P = 5.73×10(-4), odds ratio [OR] = 0.81) is associated with ER-positive breast cancer.
|
24244489 |
2013 |
|
rs10771399
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified three new breast cancer risk loci at 12p11 (rs10771399; P = 2.7 × 10(-35)), 12q24 (rs1292011; P = 4.3 × 10(-19)) and 21q21 (rs2823093; P = 1.1 × 10(-12)). rs10771399 was associated with similar relative risks for both estrogen receptor (ER)-negative and ER-positive breast cancer, whereas the other two loci were associated only with ER-positive disease.
|
22267197 |
2012 |
|
rs1292011
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified three new breast cancer risk loci at 12p11 (rs10771399; P = 2.7 × 10(-35)), 12q24 (rs1292011; P = 4.3 × 10(-19)) and 21q21 (rs2823093; P = 1.1 × 10(-12)). rs10771399 was associated with similar relative risks for both estrogen receptor (ER)-negative and ER-positive breast cancer, whereas the other two loci were associated only with ER-positive disease.
|
22267197 |
2012 |